Immunogenex Inc.
This article was originally published in Start Up
Executive Summary
Immunogenex's patent applications describe accessory molecules of the TNF family. The young company is working on an {ex vivo} gene therapy that induces disease-causing cells to express modified TNF ligands so that the offending cells will be recognized and killed by cytotoxic T-cells.